During the past decade, National Cancer Institute conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "National Cancer Institute" are "Advanced Non-Small Cell Lung Cancer" (1 trials) and "Metastatic Non Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "National Cancer Institute" in a lesser frequency.

Most popular intervention types in "National Cancer Institute" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Dacomitinib" (1 trials) and "Lorlatinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "National Cancer Institute" are 2 trials for "All" genders.

Currently, there are NaN active trials in "National Cancer Institute". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in National Cancer Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in National Cancer Institute, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".